盐酸文拉法辛缓释胶囊治疗广泛性焦虑障碍合并抑郁障碍临床对照探究.docVIP

盐酸文拉法辛缓释胶囊治疗广泛性焦虑障碍合并抑郁障碍临床对照探究【摘要】 目的 评价盐酸文拉法辛缓释胶囊(怡诺思)治疗广泛性焦虑障碍合并抑郁障碍的临床疗效和不良反应。方法 68例广泛性焦虑障碍合并抑郁障碍患者随机分为两组,分别予盐酸文拉法辛缓释胶囊(怡诺思)和安慰剂治疗,疗程8周。用汉密顿焦虑量表(HAMA)、汉密顿抑郁量表(HAMD)、临床总体印象量表(CGI)评价其疗效,药物副反应量表(TESS)评价不良反应。结果 盐酸文拉法辛缓释胶囊组显效率82.4 %,明显优于安慰剂组,不良反应少而轻。结论 盐酸文拉法辛缓释胶囊可作为一种安全有效的抗焦虑抑郁药物。 【关键词】盐酸文拉法辛缓释胶囊;广泛性焦虑障碍;抑郁障碍 Venlafaxine hydrochloride in the treatment of generalized anxiety disorder comorbidity with depressive disorder LI Ai-ping.The 3rd Teaching Hospital of Shanxi Medical Univeristy,Taiyuan 030053,China 【Abstract】 Objective To evaluate the efficacy and safety of venlafaxine hydrochloride in the treatment of generalized anxiety disorder comorbidity with depressive disorder.Methods 68 patients with gernalized anxiety disorder comorbisity with depressive disorder were randomly assigned into the velafaxinegroup and the placebo group. All the patients were treated for 8 weeks. The efficacy were measured with Hamilton AnxietyScale (HAMA),Hamilton Depression Scale(HAMD) and Clinical General Inventory(CGI).The safety was measured with Treatment Emergent SymptomScale (TESS).Results The response rate of venlafaxine group was 82.4%,which was statically higher than that of the placebo group. There were less and mild side effects in the venlafaxine group. Conclusion Venlafaxine hydrochloride is an effective and safe anti-anxiety and antidepressant. 【Key words】 Venlafaxine hydrochloride;Generalized anxiety disorder;Depressive disorder 近年来,抗抑郁的新药层出不穷,使治疗者眼花缭乱、无所适从。盐酸文拉法辛缓释剂是一种5-HT和NE再摄取抑制剂,在抑郁障碍、广泛性焦虑障碍、社交焦虑障碍、焦虑障碍共病抑郁障碍等治疗中已显现出明显的疗效和可靠的安全性。本研究以盐酸文拉法辛缓释胶囊(怡诺思)治疗广泛性焦虑障碍合并抑郁障碍,现报告如下。 1 资料和方法 1.1 一般资料 入组对象均为山西医科大学第三医院2008年7月至2009年8月的门诊和住院患者,符合美国精神障碍分类和诊断标准DSM-IV广泛性焦虑障碍合并抑郁障碍诊断标准;汉密顿焦虑量表(HAMA)14项评分≥14分、汉密顿抑郁量表(HAMD)24项评分≥8分;排除严重躯体疾病,共入组68例,随机分成两组。盐酸文拉法辛组(研究组)34例,男 16例,女 18例,年龄18～76岁,平均年龄(49.3±15.6)岁;病程6月～11年,平均(2.6±3.8)年。安慰剂组(对照组)34例,男14 例,女20例,年龄20～66岁,平均年龄(46.3±16.7)岁;病程7个月～12年,平均(3.1±2.9)年。两组年龄、性别、病程及病情严重程度均无统计学差异(P0.05)。 1.2 方法 所有患者停药清洗2周。盐酸文拉法辛和安慰剂分别装入相